DK1232260T3 - Polymorfi i det humane MDR-1-gen og anvendelser deraf - Google Patents
Polymorfi i det humane MDR-1-gen og anvendelser derafInfo
- Publication number
- DK1232260T3 DK1232260T3 DK00972654T DK00972654T DK1232260T3 DK 1232260 T3 DK1232260 T3 DK 1232260T3 DK 00972654 T DK00972654 T DK 00972654T DK 00972654 T DK00972654 T DK 00972654T DK 1232260 T3 DK1232260 T3 DK 1232260T3
- Authority
- DK
- Denmark
- Prior art keywords
- mdr
- vectors
- proteins
- polynucleotides
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99114938 | 1999-07-30 | ||
| EP00103361 | 2000-02-22 | ||
| PCT/EP2000/007314 WO2001009183A2 (en) | 1999-07-30 | 2000-07-28 | Polymorphisms in the human mdr-1 gene and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1232260T3 true DK1232260T3 (da) | 2008-02-04 |
Family
ID=26070560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00972654T DK1232260T3 (da) | 1999-07-30 | 2000-07-28 | Polymorfi i det humane MDR-1-gen og anvendelser deraf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050227249A1 (et) |
| EP (1) | EP1232260B1 (et) |
| JP (2) | JP2003510021A (et) |
| KR (1) | KR100814188B1 (et) |
| AT (1) | ATE373710T1 (et) |
| AU (1) | AU1131901A (et) |
| BG (1) | BG65988B1 (et) |
| CA (2) | CA2697207A1 (et) |
| CZ (1) | CZ2002329A3 (et) |
| DE (1) | DE60036487T2 (et) |
| DK (1) | DK1232260T3 (et) |
| EE (1) | EE200200049A (et) |
| ES (1) | ES2292481T3 (et) |
| HR (1) | HRP20020093B1 (et) |
| HU (1) | HUP0201997A3 (et) |
| MX (1) | MXPA02001094A (et) |
| NO (2) | NO330680B1 (et) |
| PL (1) | PL354034A1 (et) |
| SK (1) | SK1502002A3 (et) |
| WO (1) | WO2001009183A2 (et) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1337661A1 (en) * | 2000-11-29 | 2003-08-27 | Epidauros Biotechnologie AG | Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| WO2002043730A1 (en) * | 2000-11-29 | 2002-06-06 | Epidauros Biotechnologie Ag | Use of mdr-1 inducers for treating or preventing diseases |
| EP1389240B1 (en) | 2001-01-12 | 2009-11-18 | Washington State University Research Foundation | Mdr1 variants and methods for their use |
| WO2003025174A2 (en) * | 2001-09-06 | 2003-03-27 | Bayer Healthcare Ag | Regulation of human mrp1-like protein |
| EP1340818A1 (en) * | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| AU2003280867A1 (en) * | 2002-11-04 | 2004-06-07 | Charite-Universitatsme Dizin Berlin | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy |
| DK1756310T3 (da) * | 2004-05-12 | 2013-03-18 | Max Planck Gesellschaft | Fremgangsmåde til at påvise polymorfi i ABCB1-genet associeret med mangel af respons for et CNS-aktivt lægemiddel samt lægemiddel omfattende en ABCB1-inhibitor til anvendelse i behandlingen af CNS-relaterede sygdomme |
| JP2008545446A (ja) * | 2005-06-13 | 2008-12-18 | エフ．ホフマン−ラ ロシュ アーゲー | 急性拒絶反応に関連するｉｍｐｄｈ２ｓｎｐ |
| US20090286234A1 (en) * | 2005-06-13 | 2009-11-19 | Laurent Essioux | Il10 snp associated with acute rejection |
| CN101198708A (zh) * | 2005-06-13 | 2008-06-11 | 弗·哈夫曼-拉罗切有限公司 | 急性排斥反应中的mdr1 snp |
| WO2007058896A2 (en) * | 2005-11-10 | 2007-05-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment |
| ES2456919T3 (es) | 2007-06-12 | 2014-04-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Nuevos polimorfismos en ABCB1 asociados con una falta de respuesta clínica a medicamentos |
| KR101033840B1 (ko) * | 2011-03-08 | 2011-05-16 | (주)제일엔지니어링건축사사무소 | 공동주택용 입상관 연결구조 |
| EP3642748A4 (en) * | 2017-06-19 | 2021-03-10 | Jungla LLC | INTERPRETATION OF GENETIC AND GENOMIC VARIANTS VIA AN INTEGRATED COMPUTING AND EXPERIMENTAL FRAMEWORK FOR DEEP MUTATION LEARNING |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
| US5851819A (en) * | 1987-06-16 | 1998-12-22 | National Institutes Of Health | Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells |
| US5928637A (en) * | 1987-06-16 | 1999-07-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of inducing multidrug resistance using human MDR1 cDNA |
| JPH02100680A (ja) * | 1988-10-05 | 1990-04-12 | Suntory Ltd | ヒト正常細胞由来ｍｄｒ関連遺伝子 |
| US5399483A (en) * | 1989-03-30 | 1995-03-21 | Suntory Limited | Expression of MDR-related gene in yeast cell |
| US5856104A (en) * | 1996-10-28 | 1999-01-05 | Affymetrix, Inc. | Polymorphisms in the glucose-6 phosphate dehydrogenase locus |
| US5830697A (en) * | 1997-01-21 | 1998-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | P-glycoprotein mutant resistant to cyclosporin modulation |
-
2000
- 2000-07-28 CZ CZ2002329A patent/CZ2002329A3/cs unknown
- 2000-07-28 HU HU0201997A patent/HUP0201997A3/hu unknown
- 2000-07-28 SK SK150-2002A patent/SK1502002A3/sk unknown
- 2000-07-28 MX MXPA02001094A patent/MXPA02001094A/es active IP Right Grant
- 2000-07-28 JP JP2001513989A patent/JP2003510021A/ja active Pending
- 2000-07-28 AU AU11319/01A patent/AU1131901A/en not_active Abandoned
- 2000-07-28 CA CA2697207A patent/CA2697207A1/en not_active Abandoned
- 2000-07-28 AT AT00972654T patent/ATE373710T1/de active
- 2000-07-28 ES ES00972654T patent/ES2292481T3/es not_active Expired - Lifetime
- 2000-07-28 CA CA2376666A patent/CA2376666C/en not_active Expired - Lifetime
- 2000-07-28 EE EEP200200049A patent/EE200200049A/et unknown
- 2000-07-28 WO PCT/EP2000/007314 patent/WO2001009183A2/en active IP Right Grant
- 2000-07-28 KR KR1020027001248A patent/KR100814188B1/ko not_active IP Right Cessation
- 2000-07-28 PL PL00354034A patent/PL354034A1/xx unknown
- 2000-07-28 DE DE60036487T patent/DE60036487T2/de not_active Expired - Lifetime
- 2000-07-28 EP EP00972654A patent/EP1232260B1/en not_active Expired - Lifetime
- 2000-07-28 DK DK00972654T patent/DK1232260T3/da active
-
2002
- 2002-01-29 BG BG106362A patent/BG65988B1/bg unknown
- 2002-01-29 NO NO20020470A patent/NO330680B1/no not_active IP Right Cessation
- 2002-01-30 HR HR20020093A patent/HRP20020093B1/xx not_active IP Right Cessation
-
2004
- 2004-10-14 US US10/965,348 patent/US20050227249A1/en not_active Abandoned
-
2010
- 2010-06-02 NO NO20100798A patent/NO20100798L/no unknown
-
2011
- 2011-01-24 JP JP2011011834A patent/JP2011142909A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1232260A2 (en) | 2002-08-21 |
| ATE373710T1 (de) | 2007-10-15 |
| NO330680B1 (no) | 2011-06-06 |
| EP1232260B1 (en) | 2007-09-19 |
| HUP0201997A2 (en) | 2002-09-28 |
| KR100814188B1 (ko) | 2008-03-17 |
| CA2376666A1 (en) | 2001-02-08 |
| KR20020059347A (ko) | 2002-07-12 |
| JP2011142909A (ja) | 2011-07-28 |
| PL354034A1 (en) | 2003-12-15 |
| WO2001009183A3 (en) | 2002-03-28 |
| NO20020470D0 (no) | 2002-01-29 |
| BG106362A (bg) | 2002-09-30 |
| DE60036487D1 (de) | 2007-10-31 |
| ES2292481T3 (es) | 2008-03-16 |
| HRP20020093A2 (en) | 2004-06-30 |
| HUP0201997A3 (en) | 2005-01-28 |
| MXPA02001094A (es) | 2003-07-21 |
| CA2376666C (en) | 2010-05-25 |
| HRP20020093B1 (en) | 2011-02-28 |
| WO2001009183A2 (en) | 2001-02-08 |
| AU1131901A (en) | 2001-02-19 |
| CA2697207A1 (en) | 2001-02-08 |
| EE200200049A (et) | 2003-04-15 |
| CZ2002329A3 (cs) | 2002-07-17 |
| US20050227249A1 (en) | 2005-10-13 |
| NO20020470L (no) | 2002-03-26 |
| SK1502002A3 (en) | 2002-07-02 |
| BG65988B1 (bg) | 2010-08-31 |
| JP2003510021A (ja) | 2003-03-18 |
| DE60036487T2 (de) | 2008-06-19 |
| NO20100798L (no) | 2002-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vertegaal | Signalling mechanisms and cellular functions of SUMO | |
| Langdon et al. | A new lens for RNA localization: liquid-liquid phase separation | |
| Ye et al. | Understanding aneuploidy in cancer through the lens of system inheritance, fuzzy inheritance and emergence of new genome systems | |
| DK1232260T3 (da) | Polymorfi i det humane MDR-1-gen og anvendelser deraf | |
| BRPI0510206A (pt) | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação | |
| Gass et al. | Progranulin: an emerging target for FTLD therapies | |
| WO2004053079A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins | |
| Sun et al. | Functional and molecular expression of the proton-coupled oligopeptide transporters in spleen and macrophages from mouse and human | |
| NO20021146L (no) | Polymorfier i det humane CYP3A7 og CYP3A7 gener og deres anvendelse i diagnostikk og terapeutiske applikasjoner | |
| ATE440967T1 (de) | Auswahl von tieren für gewünschte genotypische und potentielle phänotypische eigenschaften auf der basis eines einzelnen nukleotidpolymorphismus (snp) im intron 3 des igf2-gens | |
| Chang et al. | rAAV-CRISPRa therapy corrects Rai1 haploinsufficiency and rescues selective disease features in Smith-Magenis syndrome mice | |
| Gronowicz | Personalized medicine: Promises and pitfalls | |
| Pang et al. | High-throughput sequencing offers new insights into 5-hydroxymethylcytosine | |
| DK1272663T3 (da) | Polymorfier i det humane CYP2B6-gen og deres anvendelse ved diagnostiske og terapeutiske anvendelser | |
| WO2004050860A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| WO2004013311A3 (en) | Compositions and methods relating to ovarian specific genes and proteins | |
| ATE460673T1 (de) | Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen | |
| WO2004050858A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| Holcomb et al. | GRHD PLANNING COMMITTEE | |
| Long et al. | The Role of Protocadherin γ in Adult Sensory Neurons and Skin Reinnervation | |
| ATE541040T1 (de) | Pim-3 kinase als ziel für type 2 diabetes mellitus | |
| Vlasschaert | The Evolution of the Deubiquitinating Enzyme Superfamily | |
| NAFEA et al. | Study of Vascular Endothelial Growth Factor Gene Polymorphism in Acute Myeloid Leukemia Patients | |
| Fluman | INVESTIGATING THE COUPLING MECHANISM IN THE E. COLI MULTIDRUG TRANSPORTER, MdfA, BY FLUORESCENCE SPECTROSCOPY | |
| WO2005005647A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins |